CTRL Therapeutics is a biotechnology company developing a next-generation cell therapy platform with the potential to unlock a new frontier in cell therapy for solid tumors. With broad applicability across numerous solid tumors, the company's proprietary approach for the identification and isolation of circulating tumor-reactive lymphocytes (cTRLs) has the potential to address longstanding challenges associated with cell therapy and offers key advantages over tumor-infiltrating lymphocytes (TILs). For more information, visit www.ctrl-therapeutics.com.